Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa randomized placebo-controlled study of SGC001 injection in predicted severe acute pancreatitis
CTR20263032Phase 2Active
- Sponsor
- Sungen Biomedical
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of SGC001 in acute pancreatitis (AP) (3 arms), sponsored by Sungen Biomedical. Primary endpoints: Dose-escalation stage safety and Alive and organ failure-free days. Started Aug 2026; status: active.
02
Drugs
SGC001
03
Conditions
acute pancreatitis (AP)
Beyond the preview
Go deeper on CTR20263032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263032.